{"id":2824,"date":"2021-04-01T12:05:00","date_gmt":"2021-04-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-krankenkassen-machen-werbung-fuer-arzneimittel"},"modified":"2021-04-01T12:05:00","modified_gmt":"2021-04-01T10:05:00","slug":"leserbrief-krankenkassen-machen-werbung-fuer-arzneimittel","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-krankenkassen-machen-werbung-fuer-arzneimittel","title":{"rendered":"Leserbrief: Krankenkassen machen Werbung f\u00fcr Arzneimittel"},"content":{"rendered":"<p>Fragen von Dr. S aus B.: >> Wir haben in unserer internistischen Praxis ein Schreiben von zwei gro\u00dfen Krankenkassen erhalten, in dem ziemlich offen zwei neue Arzneimittel zur Cholesterinsenkung der Firma Daiichi Sankyo beworben werden (Nilemdo\u00ae und Nustendi\u00ae). Ich frage mich, welches Interesse Krankenkassen haben, ein neues, teures Pr\u00e4parat anzupreisen, dessen Kosten-Nutzen-Relation m.E. umstritten ist. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fragen von Dr. S aus B.: >> Wir haben in unserer internistischen Praxis ein Schreiben von zwei gro\u00dfen Krankenkassen erhalten, in dem ziemlich offen zwei neue Arzneimittel zur Cholesterinsenkung der Firma Daiichi Sankyo beworben werden (Nilemdo\u00ae und Nustendi\u00ae). Ich frage mich, welches Interesse Krankenkassen haben, ein neues, teures Pr\u00e4parat anzupreisen, dessen Kosten-Nutzen-Relation m.E. umstritten ist. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[60,1272,5497,5495,1274,5496,71,68,453,498,1205,3066,456,65,56],"class_list":["post-2824","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apoplektischer-insult","tag-arteriosklerose","tag-bempedoinsaeure","tag-cgps-studie","tag-cholesterin","tag-cholesterinsenker","tag-herzinfarkt","tag-hirninfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-krankenkassen","tag-ldl-cholesterin","tag-lipidsenker","tag-myokardinfarkt","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2824"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2824\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}